CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Islet Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Islet Sciences Inc
18340 Yorba Linda Blvd Ste 107-245
Phone: (919) 480-1518p:919 480-1518 YORBA LINDA, CA  92886-4041  United States Ticker: ONCE ONCE
This company is no longer actively traded on any major stock exchange.
Business Summary
Islet Sciences, Inc. is a development-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of metabolic diseases and related indications. The Company is developing new medicines and technologies for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and metabolic disease. The Company is also developing Remogliflozin Etabonate, a new chemical entity being developed for the treatment of type 2 diabetes and NASH. In addition, the Company is developing encapsulated islet cell transplantation therapy for the treatment of type 1 or insulin-dependent diabetes; first-in-class immune-modulating small molecule IL-12 inhibitors that protect insulin-producing beta-cells from cytokines responsible for cell destruction; and a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the diagnosis of type 1 diabetes or onset of insulin dependent type 2 diabetes.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
1/31/20154/30/2014YesYes---

Industries
SIC Code Description
6770 Blank checks
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Director Gary F.Blackburn 9/1/2016 4/18/2016
Chief Executive Officer, Director ThomasLeonard 3/17/2017 3/17/2017
Chief Operating Officer David E.Wilder 61 7/26/2016 10/8/2015
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
DiaKine Therapeutics, Inc. 1414 Sachem Place Charlottesville VA United States

Business Names
Business Name
DiaKine Therapeutics, Inc.
Islet Sciences, Inc.
ISLT
ONCE

General Information
Outstanding Shares: 66,928,724 (As of 4/20/2015)
Shareholders: 109
Stock Exchange: OTC
Federal Tax Id: 870531751


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023